Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.

Nishit DhanjiTassia Cristina DecimoniMatthew T D DyerJessica R MayGijs van de WeteringSvenja PetersohnKatharina NickelAmanda SilvaDavid Q B MunizAna Paula Casagrande D Oliveira

Published in: Journal of medical economics (2023)

This analysis shows that NIVO + IPI is estimated to be a life-extending and potentially cost-saving 1L treatment option when compared with PEM + AXI for intermediate/poor-risk aRCC patients in the Brazilian private healthcare system.

Keyphrases

end stage renal disease
renal cell carcinoma
healthcare
health insurance
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
advanced non small cell lung cancer
epidermal growth factor receptor
patient reported
tyrosine kinase